Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 6
Submit an article Journal homepage
451
Views
20
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*

Amy E. DeZernDepartment of Oncology, Sidney Kimmel Cancer Center, Baltimore, MD, USA; Correspondence[email protected]
,
Amer M. ZeidanYale Cancer Center, Yale University, New Haven, CT, USA;
,
John BarnardLeukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;
,
Wesley HandDepartment of Oncology, Sidney Kimmel Cancer Center, Baltimore, MD, USA;
,
Najla Al AliHematologic Malignancies, H. Lee Moffitt Cancer Center, Tampa, FL, USA;
,
Francis BrownAdult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Cassie ZimmermanLeukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;
,
Gail J. RobozWeill Medical College of Cornell University, Leukemia Program, New York, NY, USA;
,
Guillermo Garcia-ManeroMD Anderson Comprehensive Cancer Center, Houston, TX, USA
,
David P. SteensmaAdult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Rami S. KomrokjiHematologic Malignancies, H. Lee Moffitt Cancer Center, Tampa, FL, USA;
&
Mikkael A. SekeresLeukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;
show all
Pages 1325-1331 | Received 25 Jul 2016, Accepted 02 Oct 2016, Published online: 24 Oct 2016

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Matthieu Duchmann & Raphael Itzykson. (2017) Choosing a hypomethylating agent in MDS: does gender matter?. Leukemia & Lymphoma 58:6, pages 1277-1278.
Read now

Articles from other publishers (19)

Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, D. A. Chitu, S. K. Klein, L. Griskevicius, P. J. M. Valk, J. Cloos, A. A. van de Loosdrecht, D. Breems, D. van Lammeren-Venema, R. Boersma, M. Jongen-Lavrencic, M. Söhne, R. van Marwijk Kooy, D. Deeren, M. W. M. van der Poel, M. C. Legdeur, L. Tick, E. Ammatuna, B. Löwenberg, G. J. Ossenkoppele, G. Huls, T. Pabst, G. Stussi, M. Fehr, M. G. Manz, Y. Chalandon, S. Blum & Gerwin Huls. (2023) Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer Journal 13:1.
Crossref
Sara M Tinsley-Vance, Najla Al Ali, Somedeb Ball, Luis E Aguirre, Akriti G Jain, Mohammad Omar Hussaini, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey Lancet, Eric Padron, David A Sallman & Rami S Komrokji. (2023) Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clinical Lymphoma Myeloma and Leukemia 23:5, pages 355-359.
Crossref
Arnaud Lesegretain, Andrew Brunner, Andrew J. King, Abderrahmane Laadem, Geoffrey Fell & Amir T. Fathi. (2023) Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study. Leukemia Research 125, pages 107006.
Crossref
Ken Hasegawa, Andrew H Wei, Guillermo Garcia-Manero, Naval G Daver, Nishanthan Rajakumaraswamy, Shahed Iqbal, Rebecca J Chan, Hao Hu, Preston Tse, Jiajun Yan, Michael J Zoratti, Feng Xie & David A Sallman. (2023) Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 23:2, pages 127-137.
Crossref
Michael J Hochman & Amy E DeZern. (2023) On the basis of sex: outcomes in myelodysplastic syndromes. The Lancet Haematology 10:2, pages e83-e85.
Crossref
Priscilla Kamphuis, Isabelle A. van Zeventer, Aniek O. de Graaf, Jonas B. Salzbrunn, Maaike G. J. M. van Bergen, Avinash G. Dinmohamed, Bert A. van der Reijden, Jan Jacob Schuringa, Joop H. Jansen & Gerwin Huls. (2023) Sex Differences in the Spectrum of Clonal Hematopoiesis. HemaSphere 7:2, pages e832.
Crossref
Carmelo Gurnari, Zhuoer Xie & Amer M. Zeidan. (2022) How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical Hematology International 5:1, pages 8-20.
Crossref
Marie Robin, Liesbeth C. de Wreede, Eric Padron, Katerina Bakunina, Pierre Fenaux, Linda Koster, Aziz Nazha, Dietrich W. Beelen, Raajit K. Rampal, Katja Sockel, Rami S. Komrokji, Nico Gagelmann, Dirk-Jan Eikema, Aleksandar Radujkovic, Jürgen Finke, Victoria Potter, Sally Killick, Faezeh Legrand-Izadifar, Eric Solary, Angus Broom, Guillermo Garcia-Manero, Vittorio Rizzoli, Patrick Hayden, Mrinal M Patnaik, Francesco Onida, Ibrahim Yakoub-Agha & Raphaël A. Itzykson. (2022) Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis. Blood.
Crossref
Alison R. Moliterno & Evan M. Braunstein. 2022. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B 1 24 .
Xiaorong Gu, Rita Tohme, Benjamin Tomlinson, Nneha Sakre, Metis Hasipek, Lisa Durkin, Caroline Schuerger, Dale Grabowski, Asmaa M. Zidan, Tomas Radivoyevitch, Changjin Hong, Hetty Carraway, Betty Hamilton, Ronald Sobecks, Bhumika Patel, Babal K. Jha, Eric D. Hsi, Jaroslaw Maciejewski & Yogen Saunthararajah. (2020) Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia 35:4, pages 1023-1036.
Crossref
Panagiotis T. Diamantopoulos & Nora-Athina Viniou. (2021) Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?. Leukemia Research 103, pages 106543.
Crossref
Theodoros Karantanos, Tania Jain, Alison R. Moliterno, Richard J. Jones & Amy E. DeZern. (2021) Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. International Journal of Molecular Sciences 22:5, pages 2595.
Crossref
Panagiotis T. Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, Ioannis Kotsianidis, Athanasios Galanopoulos, Helen Papadaki, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Maria Kotsopoulou, Panagiotis Repousis, Maria Dimou, Eleni Solomou, Charalampos Pontikoglou, Georgios Kyriakakis, Dimitrios Tsokanas, Menelaos-Konstantinos Papoutselis, Sotirios Papageorgiou, Alexandra Kourakli, Panayiotis Panayiotidis & Nora-Athina Viniou. (2020) Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. Clinical Lymphoma Myeloma and Leukemia 20:2, pages 114-121.
Crossref
Bryan C. Hambley & Amy E. DeZern. 2020. Diagnosis and Management of Myelodysplastic Syndromes. Diagnosis and Management of Myelodysplastic Syndromes 147 163 .
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth & Ioannis P. Trougakos. (2019) The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 47, pages 100646.
Crossref
Julia Stomper & Michael Lübbert. (2019) Can we predict responsiveness to hypomethylating agents in AML?. Seminars in Hematology 56:2, pages 118-124.
Crossref
Hong Wang, Yan Li, Na Lv, Yonghui Li, Lili Wang & Li Yu. (2018) Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes. Annals of Hematology 97:11, pages 2025-2038.
Crossref
Olha Boyko. (2018) HYPOMETHYLATING AGENTS IN TREATMENT OF MYELODYSPLASTIC SYNDROME. EUREKA: Health Sciences 3, pages 3-11.
Crossref
Andreas Due Ørskov & Kirsten Grønbæk. (2017) DNA Methyltransferase Inhibitors in Myeloid Cancer. The Cancer Journal 23:5, pages 277-285.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.